Autopsy report · NCT01814917
Long-term Extension Study of MCI-196
Cause of deathSlow enrollment
“This study has been terminated because of insufficient patient recruitment.”
Life of this trial
- Registered 5 months before it started.
- Ran for about 1 year 4 months before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Tanabe Pharma Corporation
- Sponsor type
- Industry
- Conditions
- Chronic Kidney Disease; Dialysis; Hyperphosphatemia; Paediatric
- Interventions
- colestilan; CBPB
- Participants
- 6
- Sites
- 1
- Countries
- United Kingdom
Trials that died the same way
- Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients
“This study was terminated due to inability to recruit sufficient patients.” - Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF
“The study was terminated due to difficulty in recruiting patients.” - A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
“Study terminated due to slow patient recruitment.” - All-On-4® Treatment Concept
“The study stopped as the performance of the study showed insufficient patient recruitment.” - Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection
“The study was terminated because it is very difficult to recruit more patients.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.